An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...
An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...
Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Over two dozen cases of the rare blood disorder thrombocytopenia have ...
Sanofi bags approval for Wayrilz in Japan to treat immune thrombocytopenia: Paris Wednesday, June 24, 2026, 11:00 Hrs [IST] The Ministry of Health, Labour and Welfare in Japan has ...
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results